Related Experiment Video
Updated: Jun 23, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Concurrent protective and destructive signaling of JNK2 in neuroblastoma cells
Vicki Waetzig1, Ute Wacker, Wiebke Haeusgen
1Institute of Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Hospitalstrasse 4, Kiel, Germany.
Abstract:
Investigation of the c-Jun N-terminal kinases (JNKs) has mainly focused on their response to stress and their pro-apoptotic effects. In this regard, JNKs are crucial mediators of chemotherapy-induced killing of tumor cells. Importantly, however, JNKs also have physiological functions in cancer involving cell cycle regulation or oncogenesis. Hypothetically, the composition of JNK signalosomes determines the signaling outcome which,in turn, implies a multitude of different, sometimes opposing and interfering functions. In the present study,the well-characterized human neuroblastoma cell line SH-SY5Y served as a model system to separate physiological and pro-apoptotic JNK actions in the response to the cytoskeleton-interfering substances colchicine, cytochalasin D and taxol. Basically, JNKs mediated both cell death and proliferation. Using the chemical JNK inhibitor SP600125 as well as compartment-specific JNK-inhibiting constructs and dominant negative isoform mutants, we show that the nuclear subgroup of JNK2 is the dominant effector in colchicine and taxol-induced apoptosis, while cell cycle promotion is mediated by both cytoplasmic and nuclear JNK2.In contrast, cytochalasin D-triggered apoptosis is independent of JNK signaling. Interestingly, the data of the present study demonstrate for the first time that both cell protective (cell cycle progression) and destructive mechanisms (apoptosis) are simultaneously controlled by a single JNK isoform in the same cell system even under the influence of one stimulus. This has implications for the therapeutic application of JNK inhibitors and cytoskeleton-interfering substances in oncologic disorders.
Insights
The study reveals that c-Jun N-terminal kinases (JNKs) can simultaneously promote cell survival and trigger apoptosis. Specifically, JNK2 isoforms regulate both cell cycle progression and cell death in neuroblastoma cells, impacting cancer therapy strategies.
Area of Science:
- Cell Biology
- Molecular Oncology
- Signal Transduction
Background:
- c-Jun N-terminal kinases (JNKs) are known for their role in stress response and apoptosis, crucial for chemotherapy.
- JNK signaling also contributes to physiological processes in cancer, including cell cycle regulation and oncogenesis.
- The specific functions of JNKs are hypothesized to depend on their signalosome composition, leading to diverse outcomes.
Purpose of the Study:
- To differentiate between the pro-apoptotic and physiological roles of JNKs in cancer.
- To investigate how JNK signalosome composition influences signaling outcomes.
- To elucidate the distinct functions of JNK isoforms in response to cytoskeleton-disrupting agents.
Main Methods:
- Utilized the human neuroblastoma cell line SH-SY5Y as a model system.
- Employed cytoskeleton-interfering substances: colchicine, cytochalasin D, and taxol.
- Applied JNK inhibition using SP600125, compartment-specific inhibitors, and dominant-negative mutants.
Main Results:
- JNKs were found to mediate both cell death and proliferation.
- Nuclear JNK2 was identified as the primary mediator of apoptosis induced by colchicine and taxol.
- Both cytoplasmic and nuclear JNK2 contributed to cell cycle promotion.
- Apoptosis induced by cytochalasin D was independent of JNK signaling.
- Demonstrated simultaneous control of cell-protective and cell-destructive mechanisms by a single JNK isoform.
Conclusions:
- JNK signaling exhibits dual roles, mediating both cell survival and apoptosis within the same cellular context.
- The localization and isoform of JNK (specifically JNK2) are critical determinants of its function.
- Findings have significant implications for the therapeutic use of JNK inhibitors and cytoskeleton-targeting drugs in oncology.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
